INTRODUCING AMBU® SURESIGHT™ MOBILE VIDEO LARYNGOSCOPE
Following the launch of Ambu® SureSight™ Connect in the U.S. and Great Britain in the first half of 2025, Ambu now expands its video laryngoscope portfolio with Ambu® SureSight™ Mobile – a video laryngoscope with an integrated screen for emergent and unplanned intubations across clinical settings.

Today, Ambu announces the introduction of SureSight Mobile, a portable video laryngoscope solution that expands and brings next-level flexibility to Ambu’s video laryngoscope portfolio.
Designed to be robust, reliable, and durable, the SureSight Mobile features an integrated screen without the need for separate monitors or cables. This all-in-one design enables clinicians to perform emergent and unplanned intubations swiftly and confidently in demanding environments – whether in an ambulance, emergency room, or remote location – making the SureSight Mobile a solution targeted for both pre-hospital and hospital settings. This versatile solution delivers high-quality imaging, empowering clinicians to not only visualize the airway with clarity but also seamlessly document and review the intubation process.
"There is now overwhelming evidence that video laryngoscopy enhances both the safety and efficacy of tracheal intubation compared with direct laryngoscopy. The recently published DAS 2025 Intubation Guidelines recommend that video laryngoscopes be used as the first-line approach for tracheal intubation whenever feasible. The launch of the SureSight Mobile is therefore extremely timely, enabling universal access to video laryngoscopy for all intubations across the hospital environment."
DR. IMRAN AHMAD1
Consultant Anesthetist, Guy's & St Thomas' NHS Foundation Trust, London, UK
Expanding and leveraging Ambu’s video laryngoscope portfolio
In the U.S. alone, the video laryngoscope market represents roughly DKK 4 billion and is growing 15-20% annually. Today, around 50% of all endotracheal intubations are performed with a video laryngoscope, making it the preferred intubation method across clinical settings. To support this development, Ambu’s expanded video laryngoscope portfolio now offers two SureSight video laryngoscope solutions, including a comprehensive range of 10 blades of different sizes. The breadth of Ambu’s video laryngoscope portfolio ensures that clinicians have a SureSight video laryngoscope for every setting, scenario, and preference – obtaining flexibility, reliability, and confidence across the continuum of care.
Ambu will now engage in a controlled market release phase, collaborating with clinicians at key hospitals across the U.S. and Great Britain, to evaluate the performance of the SureSight Mobile in clinical settings. Subsequently, Ambu will engage in a full launch in 2026.
"With the launch of SureSight Mobile, Ambu is reinforcing our leadership in the Respiratory market. By expanding our portfolio with a mobile video laryngoscope solution, we are addressing the needs clinicians face during unexpected intubation – when time matters most. This innovation reflects our commitment to delivering a comprehensive Respiratory offering of advanced solutions that empower healthcare professionals to make fast, confident decisions and uphold the highest standards of care across clinical settings."
BRITT MEELBY JENSEN
Chief Executive Officer, Ambu
----------------------------------------------------------------------------------
1 Dr. Ahmad has not been compensated for his quote in this press release.
Keywords
Contacts
Anders HjortHead of Investor Relations
Tel:+45 2892 8881anhj@ambu.comTine Bjørn SchmidtDirector of Corporate Communications
Tel:+45 2264 0697tisc@ambu.comABOUT AMBU
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.
Subscribe to releases from Ambu A/S
Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Ambu A/S
AMBU EXPANDS RECYCLING PROGRAM TO INCLUDE VIDEO LARYNGOSCOPE BLADES29.10.2025 14:49:09 CET | Press release
Today, Ambu announces an extension of its Ambu® Recircle Program, now to include blades from the newly launched video laryngoscopy solution, Ambu® SureSight™ Connect.
FRIENDLY REMINDER: AMBU CAPITAL MARKETS DAY 202510.9.2025 12:48:28 CEST | Press release
This is a friendly reminder to secure your seat for in-person attendance at Ambu’s Capital Markets Day, taking place on 1 October 2025 from 10:00 to 16:30 CEST at our headquarters in Denmark, Baltorpbakken 13, 2750 Ballerup. We look forward to welcoming institutional investors, analysts, and financial media for a day of insights on strategy and market opportunities. Furthermore, it is an opportunity to meet with the broader Executive Leadership Team, as well as key external speakers. Finally, there will be a product demonstration at the end of the event, offering participants the opportunity to experience Ambu’s solutions firsthand. All presentations and Q&As are held from 10:00-15:00 CEST. The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website. The product demonstration will run from 15:00-16:30 CEST and will be for in-person attendees only. SIGN UP FOR IN-PERS
AMBU APPOINTS NEW PRESIDENT OF NORTH AMERICA REGION22.8.2025 07:10:00 CEST | Press release
Steven Block steps down; Scott Heinzelman appointed as new President to drive Ambu’s strong growth trajectory in North America.
AMBU CAPITAL MARKETS DAY 20257.8.2025 15:25:11 CEST | Press release
Ambu invites institutional investors, analysts, and financial media to the company’s Capital Markets Day on Wednesday 1 October 2025.
AMBU OBTAINS FDA CLEARANCE FOR FIRST-EVER SINGLE-USE FLEXIBLE CYSTO-NEPHROSCOPY SOLUTION19.6.2025 16:43:47 CEST | Press release
The FDA clearance for the Ambu® aScope™ 5 Cysto HD marks a historic milestone as the first ever single-use cysto-nephroscope to receive such clearance in the US. It follows the CE mark in Europe earlier this year, representing an important step forward in endoscopic technology and reinforcing Ambu’s commitment to innovation and advancement in urology care.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom